MassHealth to End GLP-1 Coverage for Weight Loss, Affecting 22,000 Patients
核心洞察
MassHealth (搜索) will stop covering GLP-1 (搜索) drugs for weight loss on July 1, 2026, affecting at least 22,000 low-income Massachusetts residents.
The policy change is expected to save an estimated $15 million annually amid rising healthcare costs and anticipated federal Medicaid cuts.
Affected medications include Wegovy, Zepbound, Saxenda, Xenical, and phentermine-based drugs, with out-of-pocket costs ranging from $350 to $500 monthly.
MassHealth (搜索), Massachusetts' Medicaid program covering approximately 1.9 million residents, will terminate coverage for GLP-1 (搜索) receptor agonists and other anti-obesity (搜索) medications prescribed solely for weight loss effective July 1, 2026. The policy change, announced as part of Governor Maura Healey's fiscal 2027 budget proposal in January, is expected to affect at least 22,000 people and save the state an estimated $15 million annually.
The affected medications include Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), Xenical (orlistat), and phentermine-based drugs, according to MassHealth (搜索). Coverage will continue when these medications are prescribed for other approved medical conditions, such as Type 2 diabetes.
Rising Costs Drive Coverage Pullback
Massachusetts was among just 13 states whose Medicaid programs covered GLP-1s for weight loss at the beginning of 2026, according to the research organization KFF. The state's retreat mirrors a broader trend among major insurers and state agencies, including the Group Insurance Commission (GIC), which provides benefits to public employees, and Blue Cross Blue Shield of Massachusetts (搜索), the state's largest private insurer.
Blue Cross spent $515 million on GLP-1 (搜索) drugs last year and was on track to nearly double that spending before changing its coverage policy. The insurer cited rising premiums for all members as the driving factor.
Dr. Ryan Schwarz, assistant secretary for Massachusetts' Medicaid program, acknowledged the tension between clinical benefit and fiscal reality. "We do hope in the future, given the impact of these medications, with some changes in the pricing, we may at some point be able to offer these again," Schwarz said. "But right now, unfortunately, it is unsustainable."
Governor Healey pointed to anticipated federal Medicaid cuts under President Donald Trump's "One Big Beautiful Bill" Act as an additional budget challenge. "This is a tough situation when you take a trillion dollars out of healthcare nationally," Healey said in January. "That's a huge, huge hit for all of us."
Patients Face Difficult Choices
For MassHealth (搜索) members, who qualify for coverage due to disability or low-income status, paying out of pocket presents a significant financial burden. Wegovy carries a list price of more than $1,300 per month, while Zepbound retails at around $1,000. Manufacturer self-pay programs can lower those costs to roughly $350 to $500 per month, depending on the medication and program.
Emily Putur, a 37-year-old shop owner on the North Shore enrolled in MassHealth (搜索), described learning her prescription would no longer be covered. "It's devastating," Putur said. "Now, I'm forced to pay out of pocket, and I don't know how long I can sustain that." After starting a weekly Zepbound regimen last year, Putur lost 80 pounds and said she feels more energized. She is now seeking a second job to afford the $450 monthly cost.
Dr. Richard Siegel, co-director of the Diabetes and Lipid Center at Tufts Medical Center, said most of the dozens of messages he receives from patients daily concern struggles to access GLP-1 (搜索) drugs due to insurance restrictions. "But I think for the majority on public insurance, it's just not affordable to do that," Siegel said. "There's definitely equity issues."
Clinical Perspective and Obesity (搜索) Burden
The CDC defines obesity (搜索) as having a body mass index (BMI) of 30 or higher. In the U.S., approximately 40% of adults have obesity, with nearly one in 10 considered severely obese (BMI of 40 or higher). About 21% of children and teens have obesity. The CDC considers obesity a chronic disease that increases the risk of heart disease, Type 2 diabetes, stroke, certain cancers, liver disease, and other serious health conditions.
According to the CDC, obesity (搜索) costs the U.S. healthcare system nearly $173 billion annually. Heart attacks and strokes cost $223.2 billion per year, while diabetes costs $640 billion.
Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, strongly criticized the coverage decision. "The insurance companies are practicing blatant bias and stigma against people with obesity (搜索)," Apovian said. "If we pay upfront for these life-saving medications, down the line we will reduce healthcare dollars — the billions of dollars we spend on heart disease and diabetes and sleep apnea and liver disease."
Apovian noted that many of her patients with private insurance who already lost coverage for GLP-1s regained weight after stopping the medications. "These are drugs that you take indefinitely," she said. "Obesity (搜索) is a disease."
In 2024, the FDA expanded Wegovy's approved uses to include reducing the risk of cardiovascular death, heart attack, and stroke in adults who are obese, overweight, or have established cardiovascular disease.
Industry Response
Novo Nordisk, the maker of Wegovy, expressed disappointment with the state's decision. "Denying patients insurance coverage for safe and effective FDA-approved treatments for a serious and chronic disease is simply irresponsible," spokesperson David McAlpine said.
Eli Lilly, the maker of Zepbound, encouraged states to join a federal pilot program offering weight loss drugs to some people on public insurance at a discounted price. "We want to ensure that people with obesity (搜索) on Medicaid have access to the medicines they need, and we've worked hard to make that affordable for states," a spokesperson said.
The federal Medicare program is also planning to test an initiative that would make weight loss drugs available to seniors at a lower price, though for now, most patients on tight budgets face difficult choices about continuing these medications.